Hormonal control of plasminogen activator inhibitor-1 gene expression and production in human adipose tissue : Stimulation by glucocorticoids and inhibition by catecholamines

• Published in: The journal of clinical endocrinology and metabolism 1999-11, Vol.84 (11), p.4097-4105
• Main Authors: HALLEUX, C. M, DECLERCK, P. J, TRAN, S. L, DETRY, R, BRICHARD, S. M
• Format: Article
• Language: English
• Subjects: Adipose Tissue - metabolism; Adrenergic beta-Agonists - pharmacology; Biological and medical sciences; Catecholamines - pharmacology; Cyclic AMP - analogs & derivatives; Cyclic AMP - pharmacology; Dexamethasone - pharmacology; Dose-Response Relationship, Drug; Epinephrine - pharmacology; Female; Gene Expression Regulation - drug effects; Glucocorticoids - pharmacology; Humans; Insulin - pharmacology; Isoproterenol - pharmacology; Kinetics; Male; Medical sciences; Metabolic diseases; Middle Aged; Obesity; Obesity - metabolism; Plasminogen Activator Inhibitor 1 - genetics; RNA, Messenger - metabolism
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.84.11.4097

Plasma levels of type 1 plasminogen activator inhibitor (PAI-1), a risk factor for cardiovascular disease, are elevated in obese subjects, especially those with omental fat accumulation. We investigated the hormonal control of PAI-1 gene expression and secretion in cultured human adipose tissue. We more particularly focused on the effects of glucocorticoids, insulin, cAMP, and catecholamines in explants from the omental region. The addition of dexamethasone to the culture medium increased PAI-1 secretion in a time-dependent manner for up to 24 h. The stimulation by the glucocorticoid was preceded by a 2-fold rise in PAI-1 messenger ribonucleic acid levels between 4-8 h of culture. The effectiveness of the glucocorticoid was concentration dependent, with a half-maximal effect within a physiological range. This stimulation was also observed in sc fat, but dexamethasone-stimulated as well as basal PAI-1 secretion rates were always higher in omental fat. Unlike dexamethasone, 24-h insulin did not modify PAI-1 secretion while accelerating glucose consumption. In contrast, 24-h cAMP inhibited PAI-1 gene expression and protein production under basal conditions and in the presence of dexamethasone. This inhibition was already detectable after 1 h and was maximal after 4 h at the level of gene expression. It occurred in both omental and sc adipose tissues. Importantly, epinephrine dose dependently inhibited PAI-1 parameters, an effect that was reproduced by isoproterenol. Dexamethasone- and cAMP-induced changes in PAI-1 messenger ribonucleic acid abundance were similar in explants and isolated fat cells. In isolated stromal-vascular cells, only dexamethasone was effective. In conclusion, we provide evidence for a reciprocal regulation of PAI-1 by dexamethasone (positive effector) and cAMP/catecholamines (negative effectors) in cultured human adipose tissue. The stimulation by glucocorticoids could contribute to enhanced production of PAI-1 by adipose tissue and high plasma levels of PAI-1 associated with central obesity and thereby be a link between this disorder and cardiovascular disease. Impaired inhibition by catecholamines could also contribute, as in vivo adipose tissue responses to these hormones are usually blunted in obese individuals.